Gastrectomy|OMICS International|Journal Of Neurology And Neurophysiology

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.


Gastric cancer is a burden in medicine with a male predominant gender relation. Although the incidence of gastric cancer has decreased in the last few decades, an increase of females and elderly patients was also reported. The standard of care for gastric cancer is radical surgical resection with reported morbidity rates between 20 and 46% and a postoperative observed mortality rate between 0.8 – 10% , depending on the expertise, and in case of locally advanced tumor category ,from multimodal therapy. The Cochrane review from 2010 investigated 5,726 patients and revealed that chemotherapy significantly improves survival in advanced gastric cancer patients compared to best supportive care. The type of the surgical resection depends on the tumor location, size, cancer depth, clinical staging and the histological subtype as well as a lymphovascular invasion and contents of a radical subtotal or a total gastrectomy with D-I and/or D-II lymphadenectomy. D-I lymphadenectomy contains the perigastric lymph nodes, while a D-II lymphadenectomy contains the D-I-lymphadenectomy plus the resection of the lymph nodes along the hepatic, left gastric, celiac and splenic arteries as well as those in the splenic hilus. In western countries, the diagnosis of gastric cancer is mostly in advanced cancer tumor categories in contrast with eastern countries where most of the cases are of early cancer (about 50%).
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on January, 2021